Bang Rui Biotech - Chuang Announces Board Approval of 115 Q2 Consolidated Financial Report

1. Date of board reporting or board resolution: 115/08/10 2. Audit Committee approval date: 115/08/10 3. Reporting period for financial statements or self-compiled annual financial information: Start and end dates (YYY/MM/DD ~ YYY/MM/DD): 115/01/01 ~ 115/06/30 4. Cumulative operating revenue from January 1 to the end of this period (in thousands of NT dollars): 176,715 5. Cumulative operating gross profit (or loss) from January 1 to the end of this period (in thousands of NT dollars): 136,898 6. Cumulative operating income (or loss) from January 1 to the end of this period (in thousands of NT dollars): 55,979 7. Cumulative pre-tax net profit (or loss) from January 1 to the end of this period (in thousands of NT dollars): 60,741 8. Cumulative net profit (or loss) for the period from January 1 to the end of this period (in thousands of NT dollars): 52,338 9. Cumulative net profit (or loss) attributable to owners of the parent from January 1 to the end of this period (in thousands of NT dollars): 52,338 10. Cumulative basic earnings per share (or loss) from January 1 to the end of this period (in NT dollars): 2.11 11. Total assets at the end of the period (in thousands of NT dollars): 722,889 12. Total liabilities at the end of the period (in thousands of NT dollars): 66,173 13. Equity attributable to owners of the parent at the end of the period (in thousands of NT dollars): 656,716 14. Other matters to be disclosed: None.